Pacira BioSciences, Inc. logo

Pacira BioSciences, Inc.(PCRX)

upturn advisory logo
EXPLORE ADVISORIES AND THEIR HISTORY
QUALITY SIGNAL RECENCY
1-STAR RATING
Consider higher Upturn Star rating
BUY for 26 days
PROFIT SINCE LAST BUY
+0.41% ▲
LAST CLOSE
$36.46
11/13/2026
(24-hour delay)

Advisory History & Simulated Performance *

*as per simulation (see disclosures)
  • ALL
  • 1Y
  • 1M
  • 1W
  • BUY Advisory
  • SELL Advisory (Profit)
  • SELL Advisory (Loss)
  • Profit
  • Loss
  • PASS (Skip)
Upturn Stock price based on last close iconStock price based on last close
Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Advisory Performance History (Simulated)Advisory Performance History info

Simulated performance—not actual client returns. Excludes advisory subscription fees, trading commissions, and taxes, which would reduce returns. Results depend on calculation assumptions and do not guarantee future outcomes. See Disclosures for full methodology, assumptions, and limitations.

Upturn Advisory & Investor View for PCRX

11/13/2026: PCRX (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Pacira BioSciences is a specialty pharmaceutical company known for its non-opioid pain management products, most notably EXPAREL, which is widely used in surgical settings. The company has a leading position in the niche for extended-release local anesthetics, providing a key alternative to traditional opioid use. Its growth story hinges on successfully expanding the reach of its newer products, ZILRETTA and iovera°, to diversify revenue. However, the company faces significant risks from generic competition, ongoing patent litigation, and execution challenges in the outpatient market. This stock may suit investors focused on the biotechnology sector who are comfortable with the inherent volatility linked to clinical and regulatory developments.

How to Read the Upturn Advisory

The Upturn Star Rating and the current BUY, SELL, or PASS advisory are generated by Upturn’s AI advisory engine based on proprietary signal analysis, price behavior, advisory history, and historical signal performance.

Company fundamentals, valuation, risks, and news provide supporting context about the business.

Investor Fit

Investor styleFitWhy
Growth investorMixed fitThe company faces a maturing primary product, making growth contingent on successful pipeline execution and expansion.
Momentum investorWeak fitStock performance is currently driven by specific clinical and legal catalysts rather than sustained positive technical momentum.
Value investorMixed fitValuation may appear attractive following recent volatility, but depends heavily on the sustainability of patent protections.
Dividend investorWeak fitThe company does not pay dividends and focuses entirely on capital reinvestment.
Low-risk investorWeak fitHigh sensitivity to regulatory and patent litigation risks makes this unsuitable for low-risk portfolios.

Risk Profile

Risk factorLevelWhy it matters
Price volatilityHighThe stock often reacts sharply to patent litigation updates and clinical trial results.
Valuation riskMedium / highMarket pricing is sensitive to the long-term competitive landscape for the core EXPAREL franchise.
Competition risk (generic)HighGeneric bupivacaine formulations pose a constant threat to pricing power and market share.
Business qualityMediumWhile the product line is specialized, dependency on a narrow range of assets creates concentration risk.
Dividend incomeLow / noneThere is no income stream for investors, limiting appeal for income-oriented strategies.
Execution riskMedium / highSuccessful expansion of the iovera° and ZILRETTA franchises is critical for future diversification.

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 1.46B USD
Price to earnings Ratio 39.2
1Y Target Price 33.57
Price to earnings Ratio 39.2
1Y Target Price 33.57
Volume (30-day avg) 2.2M shares
Beta 0.22
52 Weeks Range 18.80 - 36.67
Updated Date 11/13/2026
52 Weeks Range 18.80 - 36.67
Updated Date 11/13/2026
Dividends yield (FY) -
Basic EPS (TTM) 0.93

Sector & Industry Intelligence

Sector

Healthcare

Bullish
Sentiment
Strong Bullish
Momentum
Momentum Steady
BUY participation
62.6%
Active BUY / eligible
72 / 115
30-Day BUY Count Change
+35
Market state
Strong Bullish

The number of qualifying BUY stocks has remained relatively stable.

Industry

Drug Manufacturers - Specialty & Generic

BUY participation
66.7%
Active BUY / eligible
8 / 12
30-Day BUY Count Change
+3

Sector signal summarizes BUY breadth conditions for the sector. It does not override this stock’s BUY, SELL, or PASS advisory.

Price Behavior

Strong Uptrend
PRICE PATH

Strong Uptrend

The stock has maintained a strong upward price trend across the last three quarters.

Extreme Price Shocks
PRICE STABILITY

Extreme Price Shocks

The stock has experienced exceptionally large and disruptive price movements during the period.

Analysis of Past Performance

Type Stock
Historic Profit -19.36%
Avg. Invested days 30
Today’s Advisory Consider higher Upturn Star rating
Upturn Advisory Rating upturn star rating icon
Upturn Advisory Performance Upturn Advisory Performance icon 2.0
Stock Returns Performance Upturn Returns Performance icon 1.0
Upturn Profits based on simulation icon Profits based on simulation
Upturn last close icon Last Close 11/13/2026

Upturn Scorecard

Upturn Star Rating

★★★★★
PCRX receives a 3-star rating, supported by solid company fundamentals. The rating is constrained by limited analyst upside.

Company Fundamentals

★★★★★
PCRX has solid overall fundamentals (4 stars), with moderate financial health, solid growth momentum, and solid ownership. In FY2025 versus FY2024, strong earnings growth (+107.1%) and strong cash generation (FCF margin 18.8%) are partially offset by moderate revenue growth (+3.6%), soft profitability (net margin 1.0%), modest insider ownership of 1.33%.

Financial Health Rating

★★★★★
PCRX's financial health is supported by solid liquidity, including working-capital and asset support (WC/assets 33.8%). Profitability is moderate (3 stars), which helps explain the 3-star overall score.

Growth Momentum Score

★★★★★
Earnings growth is PCRX's strongest growth driver at +107.1% FY2025 versus FY2024 (strong, 5 stars). By comparison, while revenue growth (+3.6%, moderate) and free-cash-flow growth (-23.5%, negative) hold the profile back, so recent growth is not broad-based across the business.

Ownership

★★★★★
Institutional ownership is 109.8% and approximately 98.6% of outstanding shares are publicly tradable, supporting liquidity and institutional participation. Insider ownership of 1.33% provides only moderate management-shareholder alignment.

Top 5 Institutional Investors

BlackRock Inc 16.80%
Doma Perpetual Capital Management LLC 6.96%
Vanguard Portfolio Management, LLC 6.03%
Dimensional Fund Advisors, Inc. 5.69%
State Street Corp 5.16%

Unit Economics (Per $1K Revenue)

★★★★★
PCRX generates approximately $794 of gross profit, $46 of operating income, and $188 of free cash flow for every $1,000 of revenue. Based on FY2025 results. Solid margins and strong cash conversion support a 3-star rating, while capital efficiency is weak.

Economic Dimensions

★★★★★
Effective Tax Rate: 58.31%

Quantitative Style Profile

★★★★★
PCRX has a liquid, relatively low-volatility profile. No single quantitative factor dominates as a drawback.

Style Classification

Quality Focused

Value-OrientedLow VolatilitySmall / Mid Cap RiskShort Squeeze RiskHighly Liquid / Institution-Friendly

How Company Makes Money

Business areaWhat it includesRetail investor read
Postsurgical Pain ManagementPrimary revenue from EXPAREL sales to hospitals and surgery centers.The vast majority of revenue comes from hospitals using EXPAREL to reduce patient opioid usage after surgery.
Joint and Orthopedic PainRevenue from ZILRETTA and iovera° system sales.This segment is smaller but focuses on the growing market for long-term management of osteoarthritis and joint pain.

Analyzing Revenue: Products, Geography and Growth

Revenue by Products

Product revenue - Year on Year

Earnings Date

Report Date 2026-11-05
When Before Market
Estimate 0.47
Actual 0.46

Profitability

Profit Margin 5.08%
Operating Margin (TTM) 4%

Management Effectiveness

Return on Assets (TTM) 1.49%
Return on Equity (TTM) 5.24%

Valuation

Trailing PE 39.2
Forward PE 9.9
Enterprise Value 1.50B
Price to Sales(TTM) 1.96
Enterprise Value 1.50B
Price to Sales(TTM) 1.96
Enterprise Value to Revenue 2.02
Enterprise Value to EBITDA 11.35
Shares Outstanding 39.91M
Shares Floating 39.37M
Shares Outstanding 39.91M
Shares Floating 39.37M
Percent Insiders 1.33
Percent Institutions 109.79

Financial Metrics

🧭 Investment Snapshot

Total Revenue (Scale)

Information icon Total money earned from selling products or services before any costs. It is needed to understand the scale of the business and its ability to generate income.

Net Income (Profit)

Information icon Final profit after all expenses, interest, and taxes are deducted. It is needed to determine the overall profitability available to shareholders.

Free Cash Flow (Cash Strength)

Information icon Cash remaining after operating activities and capital expenditures, showing cash available for growth. It is needed to evaluate the company’s ability to invest, pay dividends, or reduce debt.

📈 Growth & Strength

Operating Income (Core Profit)

Information icon Profit from core operations after deducting all operating expenses. It is needed to measure how efficiently the company runs its primary business activities.

EBITDA (Cash Earnings)

Information icon Earnings before interest, taxes, depreciation, and amortization, indicating operating cash potential. It is needed to compare operating performance across companies without accounting or financing differences.

Gross Profit (Unit Profitability)

Information icon Revenue minus cost of revenue, showing profit after direct production costs. It is needed to evaluate core business profitability before overhead expenses.

🛡️ Financial Safety

Cash (Liquidity Buffer)

Information icon Total cash and cash equivalents on hand. It is needed to evaluate immediate liquidity and financial flexibility.

Total Debt (Leverage Risk)

Information icon Total debt including both short-term and long-term components. It is needed to assess the company’s leverage and financial risk.

Net Working Capital (Short-Term Health)

Information icon Current assets minus current liabilities, indicating short-term liquidity strength. It is needed to assess whether the company can meet its short-term obligations.

🧱 Balance Sheet Strength

Stockholder Equity (Net Worth)

Information icon Total equity value held by shareholders. It is needed to understand the net worth of the company from the owners’ perspective.

Total Assets (Asset Base)

Information icon The full value of everything the company owns, including cash, inventory, equipment, and investments. It is needed to understand the resource base used to generate revenue.

Income Before Tax (Pre-Tax Earnings)

Information icon Income before provision for income taxes. It is needed to analyze profitability independent of tax structures.

⚙️ Cost & Drag Factors

Cost of Revenue (Production Cost)

Information icon Direct costs required to produce and deliver the products or services sold. It is needed to assess efficiency in production and service delivery.

Total Operating Expenses (Operating Cost)

Information icon Indirect costs of running the business such as salaries, marketing, and administration. It is needed to understand how much it costs to sustain ongoing business operations.

Income Tax Expense (Tax Drag)

Information icon Amount of taxes paid or payable to the government. It is needed to evaluate the impact of taxation on overall profitability.

Form CRS provides a relationship summary of our automated advisory services, flat subscription fees, and conflicts of interest. Form ADV Part 2A brochure contains complete details on services, billing, and disclosures. If any summary differs from our current regulatory filings, the filed Form ADV controls.